Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29977958 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2MAPTPOLBALDH1A1MEN1 | |
| SCHEMBL3086532 | 0.83 | SMN1; SMN2 (0.56) | SMN1; SMN2MAPTPOLBALDH1A1MEN1 | |
| SCHEMBL23845463 | 0.80 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPTPOLBALDH1A1MEN1 | |
| SCHEMBL17509 | 0.80 | SMN1; SMN2 (0.56) | SMN1; SMN2MAPTPOLBALDH1A1MEN1 | |
| SCHEMBL29483829 | 0.80 | SMN1; SMN2 (0.56) | SMN1; SMN2MAPTPOLBALDH1A1MEN1 | |
| SCHEMBL14744375 | 0.79 | MAPT (0.64) | SMN1; SMN2MAPTPOLBALDH1A1MEN1 | |
| SCHEMBL7808800 | 0.79 | NAPRT (0.51) | SMN1; SMN2MAPTALDH1A1BLMEGFR | |
| SCHEMBL2633979 | 0.78 | KDM4E (0.59) | SMN1; SMN2MAPTPOLBALDH1A1MEN1 | |
| SCHEMBL4804914 | 0.78 | SMN1; SMN2 (0.59) | SMN1; SMN2MAPTPOLBALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL4803286 | 0.78 | SMN1; SMN2 (0.55) | SMN1; SMN2MAPTPOLBALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117903115-A | Sulfone-substituted heterocyclic structure compound, preparation method thereof and application thereof in medicine | 上海致根医药科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-3419972-B1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2023-07-26 | — | — | EP | disclosed |
| US-11612599-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2023-03-28 | — | — | US | disclosed |
| CN-110494431-B | Azacyclo derivative, preparation method and medical application thereof | 苏州浦合医药科技有限公司 | 2022-11-04 | — | — | CN | disclosed |
| EP-3419971-B1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-04-20 | — | — | EP | disclosed |
| US-11213525-B2 | Linear glycosidase inhibitors | ASCENEURON SA (CH) | 2022-01-04 | — | — | US | disclosed |
| US-11213525-B2 | Linear glycosidase inhibitors | ASCENEURON SA (CH) | 2022-01-04 | — | — | US | disclosed |
| US-20210186958-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-06-24 | — | — | US | disclosed |
| US-20210077488-A1 | LINEAR GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-03-18 | — | — | US | disclosed |
| US-20210077488-A1 | LINEAR GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-03-18 | — | — | US | disclosed |
| US-20070060623-A1 | antiulcer agents; proton pump inhibitors; side effect reduction; 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; superior acid secretion inhibitory effect; peptic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, or symptomatic gastroesophageal reflux disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
| US-20070060623-A1 | antiulcer agents; proton pump inhibitors; side effect reduction; 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; superior acid secretion inhibitory effect; peptic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, or symptomatic gastroesophageal reflux disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
| WO-2007026916-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-08 | — | — | WO | disclosed |
| CN-1902196-A | Thiazole derivatives | KYOWA HAKKO KOGYO KK (JP) | 2007-01-24 | — | — | CN | disclosed |
| EP-1700856-A1 | THIAZOLE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-13 | — | — | EP | disclosed |
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| EP-1354882-A1 | DIPEPTIDYL PEPTIDASE IV INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-10-22 | — | — | EP | disclosed |
| US-6448205-B1 | FOR THE DESICCATION AND/OR DEFOLIATION OF PLANTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-09-10 | — | — | US | disclosed |
| EP-0920415-A1 | SUBSTITUTED 2-PHENYLPYRIDINE AS HERBICIDE | BASF AKTIENGESELLSCHAFT (DE) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998007700-A1 | SUBSTITUTED 2-PHENYLPYRIDINE AS HERBICIDE | BASF AKTIENGESELLSCHAFT (DE) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11213525-B2 | Linear glycosidase inhibitors | ENGASE, GAA, GLA | SMN1; SMN2 1002/4885MAPT 38/4885POLB 2024/4885 |
| US-11612599-B2 | Glycosidase inhibitors | ENGASE, GAA, GLA | SMN1; SMN2 1307/4885MAPT 24/4885POLB 2755/4885 |
| US-20210186958-A1 | GLYCOSIDASE INHIBITORS | ENGASE, GAA, GLA | SMN1; SMN2 1307/4885MAPT 24/4885POLB 2755/4885 |
| US-20070060623-A1 | antiulcer agents; proton pump inhibitors; side effect reduction; 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; superior acid secretion inhibitory effect; peptic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, or symptomatic gastroesophageal reflux disease | HRH2, GIPR, HRH4 | SMN1; SMN2 2144/4885MAPT 4809/4885POLB 4811/4885 |
| US-20210077488-A1 | LINEAR GLYCOSIDASE INHIBITORS | ENGASE, GAA, GLA | SMN1; SMN2 1002/4885MAPT 38/4885POLB 2024/4885 |
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | DPP4, DPP3, DPP9 | SMN1; SMN2 3810/4885MAPT 3376/4885POLB 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.